PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.

Seonggyu ByeonJang Ho ChoHyun Ae JungJong-Mu SunSe-Hoon LeeJin Seok AhnKeunchil ParkMyung-Ju Ahn

Published in: Cancer medicine (2020)

Given the relatively low incidence of immune-related AEs and the comparability of clinical outcomes, ICIs can be treatment option of NSCLC patients with special issues.

Keyphrases

small cell lung cancer
risk factors
advanced non small cell lung cancer
combination therapy
tyrosine kinase
epidermal growth factor receptor